2024 Q1 Form 10-K Financial Statement
#000165495424003501 Filed on March 21, 2024
Income Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $1.603M | $1.085M | $3.972M |
YoY Change | 47.72% | 31.89% | -1.28% |
% of Gross Profit | |||
Research & Development | $1.601M | $1.135M | $4.070M |
YoY Change | 34.22% | 27.65% | -27.98% |
% of Gross Profit | |||
Depreciation & Amortization | |||
YoY Change | |||
% of Gross Profit | |||
Operating Expenses | $3.204M | $2.220M | $8.042M |
YoY Change | 40.65% | 29.69% | 42.31% |
Operating Profit | -$3.204M | -$8.042M | |
YoY Change | 40.65% | -16.88% | |
Interest Expense | $69.30K | $85.86K | $247.2K |
YoY Change | 84.6% | 103.99% | 288.89% |
% of Operating Profit | |||
Other Income/Expense, Net | $1.400M | ||
YoY Change | |||
Pretax Income | -$3.134M | -$2.134M | -$7.795M |
YoY Change | 39.91% | 27.81% | -18.9% |
Income Tax | $0.00 | ||
% Of Pretax Income | |||
Net Earnings | -$3.134M | -$2.134M | -$7.795M |
YoY Change | 39.91% | 27.81% | -18.9% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$2.67 | ||
Diluted Earnings Per Share | -$0.47 | -$0.45 | -$2.67 |
COMMON SHARES | |||
Basic Shares Outstanding | 6.661M shares | 3.189M shares | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $4.734M | $7.438M | $7.438M |
YoY Change | -46.0% | 19.18% | 19.18% |
Cash & Equivalents | $4.734M | $7.438M | |
Short-Term Investments | |||
Other Short-Term Assets | $446.1K | $532.1K | $532.1K |
YoY Change | -14.54% | -22.94% | -22.94% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $5.180M | $7.979M | $7.979M |
YoY Change | -44.27% | 14.89% | 14.89% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | |||
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | -$4.00 | $4.00 | $0.00 |
YoY Change | -20.0% | -300.0% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $5.180M | $7.979M | $7.979M |
Total Long-Term Assets | -$4.00 | $4.00 | $0.00 |
Total Assets | $5.180M | $7.979M | $7.979M |
YoY Change | -44.27% | 14.89% | 14.89% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $822.5K | $866.0K | $866.0K |
YoY Change | 66.89% | 74.36% | 74.36% |
Accrued Expenses | $549.2K | $757.6K | $757.6K |
YoY Change | -23.1% | 77.87% | 77.87% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $1.372M | $1.624M | $1.624M |
YoY Change | 13.65% | 75.98% | 75.98% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $1.372M | $1.624M | $1.624M |
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
Total Liabilities | $1.372M | $1.624M | $1.624M |
YoY Change | 13.65% | 75.98% | 75.98% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$56.52M | -$53.39M | |
YoY Change | 18.16% | 17.1% | |
Common Stock | $666.00 | $393.00 | |
YoY Change | 178.66% | -68.1% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $3.808M | $6.355M | $6.355M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $5.180M | $7.979M | $7.979M |
YoY Change | -44.27% | 14.89% | 14.89% |
Cashflow Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$3.134M | -$2.134M | -$7.795M |
YoY Change | 39.91% | 27.81% | -18.9% |
Depreciation, Depletion And Amortization | |||
YoY Change | |||
Cash From Operating Activities | -$2.704M | -$1.149M | -$6.409M |
YoY Change | 63.94% | -37.06% | -27.45% |
INVESTING ACTIVITIES | |||
Capital Expenditures | |||
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | |||
YoY Change | |||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $7.606M | ||
YoY Change | 77.85% | ||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | $0.00 | 1.956M | $7.606M |
YoY Change | -100.0% | 77.84% | |
NET CHANGE | |||
Cash From Operating Activities | -$2.704M | -1.149M | -$6.409M |
Cash From Investing Activities | |||
Cash From Financing Activities | $0.00 | 1.956M | $7.606M |
Net Change In Cash | -$2.704M | 806.8K | $1.197M |
YoY Change | -207.09% | -144.2% | -126.26% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$2.704M | -$1.149M | -$6.409M |
Capital Expenditures | |||
Free Cash Flow | |||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
437102 | shares |
CY2023 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001853816 | |
CY2023 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2023 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023 | dei |
Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
|
false | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
250000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
770115 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
3930840 | shares |
CY2022 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-6400000.0 | usd |
CY2021Q3 | us-gaap |
Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
|
24106 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023 | drma |
Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
|
2924398 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023 | dei |
Document Type
DocumentType
|
10-K | |
CY2023 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2023 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-12-31 | |
CY2023 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023 | dei |
Entity File Number
EntityFileNumber
|
001-40739 | |
CY2023 | dei |
Entity Registrant Name
EntityRegistrantName
|
DERMATA THERAPEUTICS, INC. | |
CY2023 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2023 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
86-3218736 | |
CY2023 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
3525 Del Mar Heights Rd. | |
CY2023 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
322 | |
CY2023 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
San Diego | |
CY2023 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92130 | |
CY2023 | dei |
City Area Code
CityAreaCode
|
858 | |
CY2023 | dei |
Local Phone Number
LocalPhoneNumber
|
800-2543 | |
CY2023 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2023 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2023 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2023 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
CY2023 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | |
CY2023 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2023 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Public Float
EntityPublicFloat
|
4800000 | usd |
CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
6660840 | shares |
CY2023 | dei |
Auditor Firm
AuditorFirmId
|
659 | |
CY2023 | dei |
Auditor Name
AuditorName
|
Moss Adams LLP | |
CY2023 | dei |
Auditor Location
AuditorLocation
|
San Diego, California | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
250000000 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3930840 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
770115 | shares |
CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4069766 | usd |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5651041 | usd |
CY2023 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3972140 | usd |
CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4023445 | usd |
CY2023 | us-gaap |
Operating Expenses
OperatingExpenses
|
8041906 | usd |
CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
9674486 | usd |
CY2023 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8041906 | usd |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9674486 | usd |
CY2023 | us-gaap |
Interest Income Other
InterestIncomeOther
|
247216 | usd |
CY2022 | us-gaap |
Interest Income Other
InterestIncomeOther
|
63573 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7794690 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9610913 | usd |
CY2023 | drma |
Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
|
-2.67 | |
CY2022 | drma |
Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
|
-13.92 | |
CY2022 | drma |
Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
|
690666 | shares |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10107104 | usd |
CY2022 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4276365 | usd |
CY2022 | drma |
Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
|
287 | usd |
CY2022 | drma |
Issuance Of Restricted Stock Unit Awards Amount
IssuanceOfRestrictedStockUnitAwardsAmount
|
166875 | usd |
CY2022 | drma |
Issuance Of Common Stock Upon Conversion Of Restricted Stock Units Amount
IssuanceOfCommonStockUponConversionOfRestrictedStockUnitsAmount
|
0 | usd |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1082136 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9610913 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6021854 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
5651668 | usd |
CY2023 | drma |
Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
|
187 | usd |
CY2023 | drma |
Issuance Of Common Stock Upon Exercise Of Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockUponExerciseOfWarrantsNetOfIssuanceCostsAmount
|
1953957 | usd |
CY2023 | drma |
Settlement Of Fractional Shares Paid In Cash Amount
SettlementOfFractionalSharesPaidInCashAmount
|
-40 | usd |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
522082 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7794690 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6355018 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7794690 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9610913 | usd |
CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
522082 | usd |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
930325 | usd |
CY2023 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-162695 | usd |
CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-121940 | usd |
CY2023 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
369326 | usd |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-18543 | usd |
CY2023 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
331656 | usd |
CY2022 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-256973 | usd |
CY2023 | us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
1385759 | usd |
CY2022 | us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
776749 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6408931 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-8834164 | usd |
CY2023 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
7605625 | usd |
CY2022 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4276365 | usd |
CY2023 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
187 | usd |
CY2022 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
287 | usd |
CY2023 | drma |
Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
|
40 | usd |
CY2022 | drma |
Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
|
0 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7605772 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4276652 | usd |
CY2023 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
1196841 | usd |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-4557512 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
6241294 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
10798806 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7438135 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
6241294 | usd |
CY2023 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
950 | usd |
CY2022 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
950 | usd |
CY2023 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
144765 | usd |
CY2022 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | usd |
CY2023 | drma |
Incremental Fair Value Of Warrant Inducement
IncrementalFairValueOfWarrantInducement
|
2995343 | usd |
CY2022 | drma |
Incremental Fair Value Of Warrant Inducement
IncrementalFairValueOfWarrantInducement
|
0 | usd |
CY2021Q3 | drma |
Class Of Warrant Or Right Exercise Price Of Warrants Or Right
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight
|
112.00 | |
CY2023Q4 | us-gaap |
Restricted Cash Equivalents
RestrictedCashEquivalents
|
7400000 | usd |
CY2023Q4 | drma |
Accumulated Deficit
AccumulatedDeficit
|
-53400000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-6400000 | usd |
CY2023 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p> | |
CY2023 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company is exposed to credit risk in the event of a default by the financial institutions holding the Company’s cash and cash equivalents to the extent of the amounts held in excess of FDIC limits. The Company limits its credit risk by placing its cash and cash equivalents with financial institutions it believes are of high quality. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.</p> | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7794690 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9610913 | usd |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.67 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-13.92 | |
CY2023 | drma |
Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
|
2924398 | shares |
CY2022 | drma |
Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
|
690666 | shares |
CY2023 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8460771 | shares |
CY2022 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
503085 | shares |
CY2022Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
90000000 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
250000000 | shares |
CY2023Q4 | drma |
Warrants To Purchase Up To Shares Of Common Stock
WarrantsToPurchaseUpToSharesOfCommonStock
|
3472095 | shares |
CY2023Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
2.82 | |
CY2023Q4 | drma |
Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
|
0.6511 | |
CY2024Q1 | drma |
Received Net Cash Proceeds
ReceivedNetCashProceeds
|
2000000.0 | usd |
CY2024Q1 | drma |
Offering Expenses
OfferingExpenses
|
300000 | usd |
CY2023Q2 | drma |
Proceeds Cash From Pipe
ProceedsCashFromPipe
|
1500000 | usd |
CY2023Q2 | drma |
Underwriters Discounts And Offering Expenses In Pipe
UnderwritersDiscountsAndOfferingExpensesInPipe
|
300000 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2023Q4 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0.0001 | |
CY2023 | drma |
Description Of Abeyance Shares
DescriptionOfAbeyanceShares
|
the Holder left 2,730,000 shares in abeyance at the Company’s transfer agent to be delivered to the Holder at their request. The 2,730,000 shares held in abeyance were delivered to the Holder on January 8, 2024. Accordingly, as of December 31, 2023, 2,730,000 shares were held in abeyance, have not been issued and are not outstanding | |
CY2023Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
8358697 | shares |
CY2023 | drma |
Warrant Reduced Description
WarrantReducedDescription
|
from $21.20 to $2.82 per share upon closing of the March 2023 Offering | |
CY2023 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-1637000 | usd |
CY2022 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-2018000 | usd |
CY2023 | drma |
Income Tax Reconciliation Permanent And Other Difference
IncomeTaxReconciliationPermanentAndOtherDifference
|
55000 | usd |
CY2022 | drma |
Income Tax Reconciliation Permanent And Other Difference
IncomeTaxReconciliationPermanentAndOtherDifference
|
68000 | usd |
CY2023 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
86000 | usd |
CY2022 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
89000 | usd |
CY2023 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
-259000 | usd |
CY2022 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
-219000 | usd |
CY2023 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
1755000 | usd |
CY2022 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
2080000 | usd |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
2980000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
1927000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
596000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
337000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
1508000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
1068000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
246000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
311000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
5000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
49000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
129000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
17000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
5464000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
3709000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
5464000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
3709000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | usd |
CY2023Q4 | drma |
Valuation Allowance
ValuationAllowance
|
5500000 | usd |
CY2022Q4 | drma |
Valuation Allowance
ValuationAllowance
|
37000 | usd |
CY2021Q4 | drma |
Valuation Allowance
ValuationAllowance
|
1800000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
14200000 | usd |
CY2023Q4 | drma |
Net Operating Loss Carryforwards Taxable Income Offset Limit Percentage
NetOperatingLossCarryforwardsTaxableIncomeOffsetLimitPercentage
|
0.80 | pure |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
557000 | usd |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
41000 | usd |
CY2023 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
64000 | usd |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
81000 | usd |
CY2023 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
24000 | usd |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
435000 | usd |
CY2023 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
0 | usd |
CY2022 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
0 | usd |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
645000 | usd |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
557000 | usd |
CY2023Q4 | us-gaap |
Shares Outstanding
SharesOutstanding
|
101465 | shares |
CY2023Q4 | us-gaap |
Common Unit Authorized
CommonUnitAuthorized
|
102074 | shares |